Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
Graviton Bioscience (NASDAQ:MGTX) will present selective ROCK2 obesity data at the 8th Annual Evercore HealthCONx Conference on December 2, 2025 at 8:45 AM ET. CEO Samuel Waksal will lead a fireside chat covering Graviton's obesity program and its selective ROCK2 inhibitor, GV101.
Key points to be discussed include:
- Target biology: ROCK2 roles in fibrosis, inflammation, cytoskeletal mechanics, and adipose tissue.
- Preclinical efficacy: GV101 reduced lipid droplets in mouse and human adipocytes and produced weight loss in rodent models with lean mass preservation.
- Clinical significance: GV101 appears to sustain fat loss while preserving muscle.
The presentation will be webcast and open to media, investors, and the public.
Graviton Bioscience (NASDAQ:MGTX) presenterà dati selettivi sull’obesità ROCK2 all’8 ª Conferenza Annuale HealthCONx di Evercore il 2 dicembre 2025 alle 8:45 AM ET. Il CEO Samuel Waksal guiderà un colloquio informale che coprirà il programma obesità di Graviton e il suo inibitore selettivo ROCK2, GV101.
I punti chiave trattati includeranno:
- Biologia bersaglio: i ruoli di ROCK2 nella fibrosi, nell’infiammazione, nella meccanica citoscheletrica e nel tessuto adiposo.
- Efficacia preclinica: GV101 ha ridotto le goccioline di lipidi in adipociti di topo e di uomo e ha prodotto una perdita di peso in modelli murini con conservazione della massa magra.
- Significato clinico: GV101 sembra mantenere la perdita di grasso conservando la massa muscolare.
La presentazione verrà trasmessa in webcast ed aperta ai media, agli investitori e al pubblico.
Graviton Bioscience (NASDAQ:MGTX) presentará datos selectivos sobre la obesidad ROCK2 en la 8° Conferencia Anual HealthCONx de Evercore el 2 de diciembre de 2025 a las 8:45 AM ET. El CEO Samuel Waksal dirigirá una charla informal sobre el programa de obesidad de Graviton y su inhibidor selectivo de ROCK2, GV101.
Los puntos clave incluirán:
- Biología objetivo: los roles de ROCK2 en fibrosis, inflamación, mecánica citosquelética y tejido adiposo.
- Eficacia preclínica: GV101 redujo las gotídeas lipídicas en adipocitos de ratón y de humano y produjó pérdida de peso en modelos de roedores con conservación de la masa magra.
- Importancia clínica: GV101 parece mantener la pérdida de grasa mientras preserva el músculo.
La presentación se transmitirá por webcast y está abierta a medios, inversores y al público.
Graviton Bioscience (NASDAQ:MGTX)는 ROCK2 비만 데이터 중 선택적 데이터를 Evercore HealthCONx Conference의 8번째 연례 회의에서 2025년 12월 2일 동부_표준시 8:45 AM에 발표할 예정입니다. CEO Samuel Waksal은 Graviton의 비만 프로그램과 선택적 ROCK2 억제제 GV101에 대해 Fireside chat을 이끌 것입니다.
토론될 주요 요점은 다음과 같습니다:
- 타깃 생물학: 섬유화, 염증, 세포골격 역학 및 지방 조직에서 ROCK2의 역할.
- 전임상 효능: GV101은 마우스와 인간 지방세포의 지질 방울을 감소시키고, 근육량 보존과 함께 실험 동물 모델에서 체중 감소를 일으켰습니다.
- 임상적 의의: GV101은 근육을 보존하면서 지방 감소를 지속하는 것으로 보입니다.
발표는 웹캐스트로 전송되며 언론, 투자자 및 일반 대중에게 개방됩니다.
Graviton Bioscience (NASDAQ:MGTX) présentera des données sélectives sur l’obésité ROCK2 lors de la 8e conférence annuelle HealthCONx d’Evercore le 2 décembre 2025 à 8h45 ET. Le PDG Samuel Waksal animera un fireside chat couvrant le programme d’obésité de Graviton et son inhibiteur ROCK2 sélectif, GV101.
Les points clés à discuter incluent:
- Biologie cibles: les rôles de ROCK2 dans la fibrose, l’inflammation, la mécanique du cytosquelette et le tissu adipeux.
- Efficacité préclinique: GV101 a diminue les gouttelettes lipidiques dans les adipocytes souris et humains et a produit une perte de poids dans des modèles rongeurs avec préservation de la masse maigre.
- Signification clinique: GV101 semble maintenir la perte de graisse tout en préservant le muscle.
La présentation sera diffusée par webcast et ouverte aux médias, investisseurs et au grand public.
Graviton Bioscience (NASDAQ:MGTX) wird selektive ROCK2-Obesitätsdaten auf der 8. Jahresversammlung der Evercore HealthCONx Conference am 2. Dezember 2025 um 8:45 Uhr ET vorstellen. CEO Samuel Waksal wird ein Fireside-Chat leiten, der Gravitons Obesitätsprogramm und seinen selektiven ROCK2-Inhibitor GV101 behandelt.
Zu behandelnde Schwerpunkte umfassen:
- Target Biology: Rollen von ROCK2 bei Fibrose, Entzündung, zytoskelettalen Mechaniken und Fettgewebe.
- Preklinische Wirksamkeit: GV101 reduzierte Lipidtröpfchen in Maus- und menschlichen Adipozyten und führte in Modellorganismen zu Gewichtsverlust bei Erhaltung der Magermasse.
- Klinische Bedeutung: GV101 scheint Fettverlust zu erhalten, während Muskelmasse erhalten bleibt.
Die Präsentation wird gestreamt und steht Medien, Investoren und der Öffentlichkeit offen.
Graviton Bioscience (NASDAQ:MGTX) سيعرض بيانات اختيارية عن السمنة ROCK2 في المؤتمر الثامن السنوي Evercore HealthCONx في 2 ديسمبر 2025 الساعة 8:45 صباحاً بتوقيت شرق الولايات المتحدة. سيقود الرئيس التنفيذي Samuel Waksal جلسة حوار بجانب الموقد تغطي برنامج Graviton للسمنة ومثبط ROCK2 الانتقائي GV101.
النقاط الرئيسية التي ستناقش تشمل:
- البيولوجيا المستهدفة: أدوار ROCK2 في التليف، الالتهاب، ميكانيكا الهيكل الخلوي، والنسيج الدهني.
- الفعالية قبل السريرية: GV101 قلل من القطيرات الدهنية في الخلايا الدهنية عند الفئران والبشر وأدى إلى فقدان وزن في نماذج القوارض مع الحفاظ على الكتلة الخالية من الدهون.
- الأهمية السريرية: GV101 يبدو أنه يحافظ على فقدان الدهون مع الحفاظ على العضلة.
سيتم بث العرض عبر البث المباشر وسيكون مفتوحاً للصحافة والمستثمرين والجمهور.
- None.
- None.
- Tuesday, December 2, 2025 at 8:45am Eastern Time
The fireside chat will provide an overview of Graviton's obesity research program and selective ROCK2 inhibitor development, highlighting:
-
Target Biology
. ROCK2 (Rho-associated coiled-coil containing protein kinase 2) is involved in fibrosis, inflammation, and cytoskeletal mechanics, as well as being present in adipose tissue; Graviton's GV101 is a highly selective ROCK2 inhibitor.
-
Preclinical Efficacy
. In rodent obesity models, GV101 reduces lipid droplets both in mouse and human adipocytes. Graviton's ROCK2 inhibitors decrease weight similarly to GLP-1 RAs with relative lean mass preservation.
- Clinical Significance . GV101 appears to lead to sustained fat loss while preserving muscle, thus promoting healthier weight loss.
The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors, and the general public.
About Graviton Bioscience
Graviton Bioscience Corporation is a clinical stage drug discovery and development company, dedicated to engineering and developing best-in-class therapeutics for treating metabolic, CNS, inflammatory, fibrotic, and multiple other disease indications including where ROCK2 plays a pivotal role in pathology. Graviton's first drug candidate, GV101, is in clinical studies, with additional assets advancing through the preclinical pipeline. Leading the company is Dr. Samuel Waksal, the founder and former Chairman and CEO of Kadmon Pharmaceuticals (acquired by Sanofi). Dr. Waksal is also the founder and former CEO of ImClone Systems (acquired by Eli Lilly) and a founder of MeiraGTx (NASDAQ: MGTX).
Forward-Looking Statements
This press release contains forward-looking statements regarding Graviton's development plans, regulatory strategy, and potential future clinical applications for its selective ROCK2 inhibitors. Such statements are subject to risks and uncertainties, including, but not limited to, biological, clinical, regulatory, financial, and operational risks. Actual results may differ materially.
Graviton Bioscience Contact:
Melanie Glickman
Senior Associate, Operations Strategy
Melanie.Glickman@gravitoncorp.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/graviton-bioscience-to-present-selective-rock2-obesity-data-at-8th-annual-evercore-healthconx-conference-302622251.html
SOURCE Graviton Bioscience
FAQ
When will Graviton Bioscience (MGTX) present at Evercore HealthCONx?
What will Graviton discuss about GV101 at the MGTX presentation?
Does Graviton (MGTX) report clinical results for GV101 at the conference?
How did GV101 perform in preclinical obesity models according to Graviton's announcement?
Will the Graviton (MGTX) fireside chat be available to investors online?
What aspects of ROCK2 will Graviton highlight for its obesity program?
